Tag : ERLEADA

Latest News

Erleada Drug Insight Report, 2019: Drug Overview, Mechanism of Action, Clinical Trials, Regulatory Milestones, Deals, Partnerships, and Sales Forecasting to 2021 – ResearchAndMarkets.com

Newsemia
DUBLIN–(BUSINESS WIRE)–The “Erleada – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Erleada – Drug Insight, 2019 report provides comprehensive information of the...
Latest News

Aktualisierte Ergebnisse der SPARTAN-Studie zeigen Reduzierung des Mortalitätsrisikos um 25 Prozent durch die Behandlung von Patienten mit nicht metastasiertem, kastrationsresistentem Prostatakarzinom (nmCRPC) mit ERLEADA® (Apalutamid)

Newsemia
BARCELONA, Spanien–(BUSINESS WIRE)–Die Janssen Pharmaceutical Companies von Johnson & Johnson haben heute die aktualisierten, langfristigen Ergebnisse der Phase-3-Zulassungsstudie SPARTAN nach einer zweiten Zwischenanalyse bekanntgegeben. Die...
Latest News

Riassunto: Janssen riceve un'opinione positiva dal CHMP per ERLEADA™ (apalutamide) per pazienti affetti da carcinoma della prostata non-metastatico resistente alla castrazione ad alto rischio di sviluppo di malattia metastatica

Newsemia
BEERSE, Belgio–(BUSINESS WIRE)–Le società Janssen Pharmaceutical di Johnson & Johnson hanno annunciato oggi che la Commissione per i prodotti medicinali per uso umano (CHMP) dell’Agenzia...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy